Dose reduction and high-risk disease as risk factors for early death in primary CNS lymphoma

Leuk Lymphoma. 2020 Jan;61(1):240-242. doi: 10.1080/10428194.2019.1650176. Epub 2019 Aug 8.

Authors

Vanja Zeremski^{1

2}, Thomas Fischer^{1

2}, Enrico Schalk^{1

2}

Affiliations

¹ Department of Hematology and Oncology, Medical Center, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
² Health Campus Immunology, Infectiology and Inflammation (GC-I³), Medical Center, Otto-von-Guericke University, Magdeburg, Germany.

PMID: 31393196
DOI: 10.1080/10428194.2019.1650176

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Central Nervous System Neoplasms* / drug therapy
Central Nervous System Neoplasms* / epidemiology
Drug Tapering
Humans
Lymphoma, Non-Hodgkin* / diagnosis
Lymphoma, Non-Hodgkin* / drug therapy
Risk Factors